SM03

DRUG2 trials

Sponsors

SinoMab BioScience Ltd

Conditions

Rheumatoid ArthritisRheumatoid Arthritis(RA)

Phase 2

A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate

CompletedNCT04192617

SinoMab BioScience LtdRheumatoid Arthritis

Start: 2014-12-31End: 2016-02-03Updated: 2019-12-10

Phase 3

A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX

SinoMab BioScience LtdRheumatoid Arthritis(RA)

Start: 2017-12-28End: 2022-07-31Target: 510Updated: 2021-01-08

Related Papers

SM03, an Anti-CD22 Antibody, Converts <i>Cis</i>-to-<i>Trans</i> Ligand Binding of CD22 against α2,6-Linked Sialic Acid Glycans and Immunomodulates Systemic Autoimmune Diseases

The Journal of Immunology2022-06-0114 citations

SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study

Lara D. Veeken2021-09-0812 citations